APA (7th ed.) Citation

M, S., M, H., C, S., M, P., N, P., N, L., . . . M, J. (2026). Response-guided bulevirtide ± pegylated interferon alfa-2a: Long-term outcomes observed in the nationwide Austrian hepatitis D cohort study. JHEP reports : innovation in hepatology, 8(6), 101835. https://doi.org/10.1016/j.jhepr.2026.101835

Chicago Style (17th ed.) Citation

M, Schwarz, et al. "Response-guided Bulevirtide ± Pegylated Interferon Alfa-2a: Long-term Outcomes Observed in the Nationwide Austrian Hepatitis D Cohort Study." JHEP Reports : Innovation in Hepatology 8, no. 6 (2026): 101835. https://doi.org/10.1016/j.jhepr.2026.101835.

MLA (9th ed.) Citation

M, Schwarz, et al. "Response-guided Bulevirtide ± Pegylated Interferon Alfa-2a: Long-term Outcomes Observed in the Nationwide Austrian Hepatitis D Cohort Study." JHEP Reports : Innovation in Hepatology, vol. 8, no. 6, 2026, p. 101835, https://doi.org/10.1016/j.jhepr.2026.101835.